Opportunities this week:
- We are reiterating our BUY rating on GSK following a reassuring Zantac related news update. (BUY PT: £18.90)
- We are reiterating our BUY rating on CRH after its solid Q2 2024 results release. (BUY PT: $93.10)
- We are reiterating our BUY rating on FBD following a positive meeting with management last week. (BUY PT: €16.00)